Working… Menu

Relative Bioavailability of Folic Acid and L-5-Methlytetrahydrofolate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01584050
Recruitment Status : Completed
First Posted : April 24, 2012
Last Update Posted : August 10, 2012
Information provided by (Responsible Party):
University of British Columbia

Brief Summary:
Folic acid, a form of the vitamin folate, is added to grain products in Canada to help reduce birth defects. Folic acid is the synthetic form of folate and is very stable (doesn't break down) when added to foods. There are emerging health concerns about chronic folic acid consumption. Recently another more natural form of folate, L-5-methyltetrahydrofolate (L-MTHF) has become available. The investigators plan to conduct a randomized trial in women to determine if supplements containing L-MTHF consumed over three months raises blood folate levels as much as supplements containing folic acid. The investigators hypothesize that L-MTHF will increase red cell folate over 12 weeks to same extent as equimolar folic acid.

Condition or disease Intervention/treatment Phase
Vitamin B12 Deficiency Dietary Supplement: L-5-methyltetrahydrofolate (Metafolin ®) Dietary Supplement: folic acid Dietary Supplement: Placebo Not Applicable

Detailed Description:

The proposed study is a twelve week, cross-sectional, double blind, randomized controlled trial. The sample population will consist of one-hundred fifty healthy adult volunteers. All participants will be Malaysian women between eighteen and forty-two years of age. Study participants will be recruited by word of mouth and through advertisements placed in hospitals and universities starting in January 2011. Study participants will be randomly assigned to 1 of 3 treatment groups: 1) 1000ug L-MTHF 2) 1000ug folic acid 3) placebo (methyl cellulose). All treatments will be given in capsule form. Blood samples will be collected at baseline, 6 and 12 weeks.

The primary outcome measure is red cell folate. A sample size of 45 subjects per group will allow us to detect a minimum difference of 100 nmol/L red cell folate assuming an alpha 0.05, a beta of 0.8 a SD of 183 nmol/L. Accounting for a 10% attrition rate we will enroll 50 women per group. The study will be analyzed as intent to treat. Baseline characteristics and compliance between treatment groups will be compared using a one-way ANOVA for continuous variables and chi-square analyses for categorical variables. The difference in measurements between the treatment groups at week 12 will be determined by regression analysis, controlling for baseline values.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: Relative Bioavailability of Folic Acid and L-5-Methlytetrahydrofolate
Study Start Date : May 2012
Actual Primary Completion Date : July 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: L-MTHF Dietary Supplement: L-5-methyltetrahydrofolate (Metafolin ®)
dosage: 1000 μg, frequency: once daily, duration: 12 weeks

Active Comparator: folic acid Dietary Supplement: folic acid
dosage: 1000 μg, frequency: once daily, duration: 12 weeks

Placebo Comparator: placebo (methyl cellulose) Dietary Supplement: Placebo
frequency: once daily, duration: 12 weeks

Primary Outcome Measures :
  1. Red cell folate (nmol/L) [ Time Frame: 12 weeks ]
    Measured at baseline, 6 weeks, 12 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Malaysian nationality

Exclusion Criteria:

  • Pregnancy
  • Vitamin supplement users
  • Chronic disease
  • prior neural tube defect affected pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01584050

Layout table for location information
Canada, British Columbia
University of British Columbia
Vancouver, British Columbia, Canada
Universiti Putra Malaysia
Serdang, Selangor, Malaysia
Sponsors and Collaborators
University of British Columbia
Layout table for investigator information
Principal Investigator: Tim Green, PhD University of British Columbia
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of British Columbia Identifier: NCT01584050    
Other Study ID Numbers: H10-03426
First Posted: April 24, 2012    Key Record Dates
Last Update Posted: August 10, 2012
Last Verified: August 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin B 12 Deficiency
Vitamin B Deficiency
Deficiency Diseases
Nutrition Disorders
Folic Acid
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs